目的 探討還原型谷胱甘肽聯合重組人促紅素治療尿毒癥貧血患者的有效性與安全性。方法 選擇2014年1月-2016年5月在鄭州市第七人民醫(yī)院診治的尿毒癥貧血患者84例作為研究對象，根據隨機信封抽簽原則分為觀察組與對照組各42例，對照組給予血液透析與口服促紅細胞生成素治療，觀察組在對照組治療的基礎上給予還原型谷胱甘肽治療，兩組均治療觀察12周。結果 兩組治療期間都無嚴重并發(fā)癥發(fā)生，治療后觀察組總有效率（97.6%）明顯高于對照組（85.7%），差異有統(tǒng)計學意義（P<0.05）。觀察組與對照組治療后的血清尿酸（UA）值明顯低于治療前，而血清內生肌酐清除率（Ccr）明顯高于治療前，組內對比都有統(tǒng)計學意義（P<0.05）；同時治療后觀察組的血清UA明顯低于對照組，Ccr值明顯高于對照組，差異有統(tǒng)計學意義（P<0.05）。觀察組治療后的血紅細胞（RBC）與血紅蛋白（Hb）值分別為（3.38±0.34）×10¹²/L和（94.55±4.92）g/L，而對照組分別為（2.56±0.38）×10¹²/L和（73.24±5.39）g/L，都明顯高于治療前（P<0.05），且觀察組也明顯高于對照組，差異有統(tǒng)計學意義（P<0.05）。結論 還原型谷胱甘肽聯合重組人促紅素治療尿毒癥貧血患者可改善腎功能與貧血狀態(tài)，提高治療療效，安全性好，有很好的應用推廣價值。

Objective To explore the effectiveness and safety of reduced glutathione in the treatment of uremic patients with anemia. Methods From January 2014 to May 2016, 84 uremic patients with anemia in our hospital for treatment were selected as the research object and were equally divided into the observation group and control group with 42 patients in each group accorded to the random draw envelope principle. The control group was treated with hemodialysis and oral administration of erythropoietin therapy, the observation group was received the reduced glutathione treatment based on the control group, all patients were observed for 12 weeks. Results There were no serious complications in the two groups. The total effective rate of the observation group and the control group were 97.6% and 85.7% respectively. The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). The serum UA values in observation group and the control group after treatment were significantly lower than that before treatment, the serum Ccr value were significantly higher than before treatment (P<0.05), At the same time after treatment, the serum UA and Ccr values in the observation group compared with the control group were statistical significance difference (P<0.05). The RBC and Hb in the observation group after treatment were (3.38 ±0.34)×10¹²/L and (94.55 ±4.92) g/L, and the control group were (2.56 ±0.38)×10¹²/L and (73.24 ±5.39) g/L respectively that were significantly higher than before treatment (P<0.05), and the observation group were significantly higher than those in control group (P<0.05). Conclusion Reduced glutathione in the treatment of uremic anemia can improve renal function and anemia status, improve the therapeutic efficacy, its better safety, and has a good value of application and promotion.